Onset of vitiligo during bimekizumab treatment for psoriasis
Therapies · 2026-09
DOI: 10.1016/j.therap.2026.09.044 ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapies, 2026-09. Verfasst von Elodie Potereau und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology-Toxicology and Pharmacovigilance, University Hospital of Angers, 49100 Angers, France. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Psoriasis is an inflammatory skin disorder characterized by epithelial hyperplasia and infiltration of inflammatory cells. Several immunological therapies have been developed for its treatment, including IL-17 inhibitors such as secukinumab, ixekizumab and bimekizumab. The safety profile of IL-17 inhibitors includes infectious diseases, gastrointestinal disorders, headaches, and cutaneous conditions such as eczema. Here, we report the first case of vitiligo, a depigmenting skin disorder characterized by the selective loss of melanocytes, occurring during treatment with bimekizumab. This case involved a 42-year-old man who achieved complete skin clearance of psoriasis plaques under bimekizumab therapy. After 11 months of treatment, he developed vitiligo patches on his face. These lesions resolved following discontinuation of bimekizumab, minipulse therapy and ruxolitinib cream application. Vitiligo occurrence has been previously observed with other IL-17 inhibitors, including secukinumab and ixekizumab (11 other cases). Although IL-17 is believed to play a role in the pathophysiology of vitiligo, its exact mechanism remains unclear. Paradoxal vitiligo may represent a class effect of IL-17 inhibitors, particularly in patients with psoriasis. This potential adverse effect should be considered, especially in patients with a personal or family history of vitiligo or other depigmentation disorders. Interestingly, stability or even repigmentation has been observed in patients who continued anti-IL-17 therapy, regardless of whether they received symptomatic treatment. Given the efficacy of anti-IL17 inhibitors in psoriasis, the risk-benefit balance should be carefully discussed in this context.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacology-Toxicology and Pharmacovigilance, University Hospital of Angers, 49100 Angers, France.
- Department of Dermatology, University Hospital of Angers, 49100 Angers, France.
- Department of Medical Pharmacology, Centre of Pharmacovigilance and Pharmacoepidemiology, University Hospital of Rennes, Rennes, France.
- Department of Pharmacology-Toxicology and Pharmacovigilance, University Hospital of Angers, 49100 Angers, France; Angers University, 49035 Angers, France; Research Institute MitoVasc, UMR CNRS 6214 Inserm 1083, 49100 An…
Zitieren
APA
Potereau, E., Le Corre, Y., Polard, E., Briet, M., & Babin, M. (2026). Onset of vitiligo during bimekizumab treatment for psoriasis. Therapies. https://doi.org/10.1016/j.therap.2026.09.044
Vancouver
Potereau E, Le Corre Y, Polard E, Briet M, Babin M. Onset of vitiligo during bimekizumab treatment for psoriasis. Therapies. 2026. doi:10.1016/j.therap.2026.09.044
BibTeX
@article{Potereau2026,
author = {Potereau, Elodie and Le Corre, Yannick and Polard, Elisabeth and Briet, Marie and Babin, Marina},
title = {Onset of vitiligo during bimekizumab treatment for psoriasis},
journal = {Therapies},
year = {2026},
doi = {10.1016/j.therap.2026.09.044}
}
EUVIMED